AQSTAquestive Therapeutics, Inc.
$4.77-20% 1Y
$4.77
$2.9552 weeks$7.49
The financials
Aquestive Therapeutics, Inc. by the numbers
Aquestive Therapeutics, Inc. (AQST) reported revenue of $14M in Q2 2026 (quarter ended Jun 30, 2026), up 38% from the same quarter a year earlier. That came with a gross margin of 71% and net loss of $23M. For the full year FY2025, revenue was $45M (−23% year on year) and net income −$84M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $14M | $10M | +38% |
| Gross profit | $9.8M | $5.4M | +80% |
| Operating income | −$8.2M | −$11M | n/a |
| Net income | −$23M | −$14M | n/a |
| Diluted EPS | −$0.18 | −$0.14 | n/a |
Drug Manufacturers, Specialty & Generic
Ranks #37 of 41 by RyuScore